COPYRIGHT © DIGITAL JOURNAL INC. Sitemaps: XML / News. Digital Journal is not responsible for the content of external sites. Read more about our external linking
DelveInsight’s, “Histone Deacetylase 6 (HDAC 6) Inhibitors Pipeline Insight 2023,” report provides comprehensive insights about 20+ companies and 26+ pipeline drugs in Histone Deacetylase 6 (HDAC 6) Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Histone deacetylase (HDAC) Inhibitors Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Histone deacetylase (HDAC) Inhibitors clinical trial studies, Histone deacetylase (HDAC) Inhibitors NDA approvals (if any), and product development activities comprising the technology, Histone Deacetylase 6 (HDAC 6) Inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Histone deacetylase (HDAC) Inhibitors Pipeline Report
To explore more information on the latest breakthroughs in the Histone deacetylase (HDAC) Inhibitors Pipeline treatment landscape of the report, click here @ Histone deacetylase (HDAC) Inhibitors Pipeline Outlook
Histone deacetylase (HDAC) Inhibitors Overview
Development of isoform-selective histone deacetylase (HDAC) inhibitors is important in elucidating the function of individual HDAC enzymes and their potential as therapeutic agents. Among the eleven zinc-dependent HDACs in humans, HDAC6 is structurally and functionally unique. Histone deacetylase 6 (HDAC6) is unique among the eleven zinc-dependent HDACs in humans. HDAC6 is located in the cytoplasm, and it has two catalytic domains and an ubiquitin-binding domain at the C-terminal region.
Recent Developmental Activities in the Histone deacetylase (HDAC) Inhibitors Treatment Landscape
For further information, refer to the detailed Histone deacetylase (HDAC) Inhibitors Unmet Needs, Histone deacetylase (HDAC) Inhibitors Market Drivers, and Histone deacetylase (HDAC) Inhibitors Market Barriers, click here for Histone deacetylase (HDAC) Inhibitors Ongoing Clinical Trial Analysis
Histone deacetylase (HDAC) Inhibitors Emerging Drugs Profile
Ricolinostat, an oral, selective histone deacetylase 6 (HDAC6) inhibitor, has the potential to become the first-in-class treatment that reverses the underlying peripheral neuropathy, thereby relieving pain, numbness, motor function loss, and all other symptoms of the disease. Ricolinostat restores nerve function by inhibiting HDAC6, which reestablishes the transport function of microtubules in the axon of the nerve cell. Multiple preclinical animal models have demonstrated that HDAC6 inhibition restores nerve fibers, leading to the reversal of both pain and numbness in peripheral and other neuropathies, such as chemotherapy-induced peripheral neuropathy and Charcot-Marie-Tooth disease Type 2, an orphan-designated disease. It is currently being evaluated in Phase II clinical trial to treat Diabetic peripheral neuropathy.
CKD 504 is HDAC6 protein inhibitor currently being developed and investigated in Phase II stage of development for the treatment of Rheumatoid Arthritis. The drug reduces inflammation by inhibiting histone deacetylase 6 (HDAC6) thus affecting inflammatory diseases and enhancing the T-cell function to boost immune response.
Resminostat is an orally administered histone deacetylase (HDAC) inhibitor that potentially represents a novel therapy for a broad spectrum of oncology indications, both in monotherapy and particularly in combination with other anti-cancer drugs. In preclinical models, resminostat has shown selectivity for class I, IIB and IV HDAC enzymes with a particular specificity toward inhibiting the protein HDAC6, which is active in metastasis. Resminostat has the potential to provide significant benefit to patients by inhibiting tumor progression and metastasis, inducing tumor regression and enhancing the body’s own immune response to cancer. In July 2020 4SC initiated a Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of 4SC-201 and the Treatment Combination of Sorafenib Plus 4SC-201 in Patients With Hepatocellular Carcinoma Exhibiting Progressive Disease Under Sorafenib Treatment.
KA2507 is a highly-selective and potent inhibitor of the tubulin deacetylase, HDAC6. Selective inhibition of this enzyme confers a cancer immunotherapeutic response by regulating immune checkpoint markers within the tumor microenvironment. HDAC6 has also emerged as a potentially important therapeutic target due to its overexpression in solid tumors and its role in specific mutant-harboring cancers. Karus considers KA2507 to hold broad therapeutic potential for the treatment of solid tumors, as both a single agent and in combination with other drugs. The drug is currently being evaluated in Phase I stage of development.
Histone deacetylase (HDAC) Inhibitors Pipeline Therapeutics Assessment
There are approx. 20+ key companies which are developing the therapies for Histone Deacetylase 6 (HDAC 6) Inhibitors. The companies which have their Histone Deacetylase 6 (HDAC 6) Inhibitors drug candidates in the most advanced stage, i.e. Phase II include Regenacy Pharmaceuticals.
Request a sample and discover the recent advances in Histone deacetylase (HDAC) Inhibitors Ongoing Clinical Trial Analysis and Medications, click here @ Histone deacetylase (HDAC) Inhibitors Treatment Landscape
Scope of the Histone deacetylase (HDAC) Inhibitors Pipeline Report
Dive deep into rich insights for drugs for Histone deacetylase (HDAC) Inhibitors Market Drivers and Histone deacetylase (HDAC) Inhibitors Market Barriers, click here @ Histone deacetylase (HDAC) Inhibitors Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Histone deacetylase (HDAC) Inhibitors Mergers and acquisitions, Histone deacetylase (HDAC) Inhibitors Licensing Activities @ Histone deacetylase (HDAC) Inhibitors Emerging Drugs, and Recent Trends
List of Top Selling Market Research Reports in 2023
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash Bhardwaj
info@delveinsight.com